Codexis, INC 10-Q quarterly reports

Codexis, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting an increase in product revenue but a continued net loss, alongside a significant decrease in cash and cash equivalents.

Codexis, Inc. announced its first quarter 2026 financial results, reporting a significant increase in total revenues driven by strong growth in research and development revenue.

Codexis reports a decrease in total revenues for Q3 and YTD 2025, alongside a narrower net loss, as it focuses on its ECO Synthesis platform and implements a workforce reduction.

Codexis, Inc. reported a significantly reduced net loss in the second quarter of 2025, driven by a substantial increase in research and development revenue and improved product gross margins, despite a year-to-date revenue decline.

Codexis' Q1 2025 results reveal a significant drop in revenue, primarily due to lower product and research and development revenue, as the company focuses on its pharma biocatalysis business and ECO Synthesis platform.

Codexis saw a significant jump in product revenue during the third quarter of 2024, but overall losses continued due to decreased research and development revenue and increased operating expenses.

Codexis, Inc. reports a significant decrease in revenue for the second quarter of 2024, driven by lower product sales and research and development revenue, as the company focuses on its core pharmaceutical manufacturing business and ECO Synthesis platform.

Codexis' first quarter of 2024 saw a significant increase in revenue, driven by both product sales and research and development, while also reducing its net loss compared to the same period last year.